Inactief instrument

Andere talen Hutchison China MediTech Limited London S.E.

Aandelen

KYG4672N1198

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

HUTCHMED Limited Appoints Dr. Renu Bhatia as an Independent Non-Executive Director and a Member of Technical Committee, Effective May 13, 2024	08/05
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda	29/04
EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug	26/04
Hutchmed notes CHMP's positive opinion for fruiquintinib approval	26/04
European Medicines Agency Committee Backs Approval of Takeda's Fruquintinib to Treat Colorectal Cancer	26/04
Hutchmed to Present New Data at US Cancer Research Conference	05/04
HUTCHMED Limited Highlights Data to be Presented at AACR Congress 2024	05/04
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status	03/04
Hutchmed endometrial cancer treatment application accepted for review	02/04
Hutchmed, Innovent Biologics Say Chinese Regulator Accepts Application for Endometrial Cancer Drug Combination	02/04
HSBC in special payout on Canada sale; Astra FDA win	02/04
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status	02/04
Sector Update: Health Care Stocks Advance Premarket Thursday	28/03
Hutchmed lung cancer treatment accepted for review in China	28/03
Hutchmed Says Supplemental New Drug Application for Savolitinib Accepted for Review in China	28/03
JD Sports backs outlook; Spirent accepts new offer	28/03
Hutchmed (China)'s NDA Application Accepted by Chinese Authorities	28/03
HUTCHMED Limited Announces Savolitinib sNDA Accepted in China for Treatment-Naive or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC	28/03
Hutchmed begins registration stage for sovleplenib phase 2/3 trial	22/03
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug	22/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Hutchison China MediTech Limited London S.E.

Aandelen

KYG4672N1198

Andere talen

Filters